Sorafenib-induced premalignant and malignant skin lesions

International Journal of Dermatology

Volumn 50, Issue 4, 2011, Pages 396-402

  Williams, Victoria L ^a   Cohen, Philip R ^b,c,d   Stewart, David J ^e  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF HOUSTON   (United States)

^d University of Texas Health Science Center at Houston   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB; SURAMIN;

AGED; CANCER INVASION; CASE REPORT; CRYOTHERAPY; DOWNSTREAM PROCESSING; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG WITHDRAWAL; EPIDERMIS; FOLLOW UP; HUMAN; LUNG ADENOCARCINOMA; MALE; MONOTHERAPY; PRECANCER; PRIMARY TUMOR; REVIEW; RISK ASSESSMENT; SKIN CANCER; SKIN DEFECT; SKIN TUMOR; SOLID TUMOR; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; HUMANS; PRECANCEROUS CONDITIONS; PROTEIN KINASE INHIBITORS; PYRIDINES; SKIN NEOPLASMS;

EID: 79952765808     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2010.04822.x     Document Type: Review

References (42)

1. Shchemelinin I, Sefc L, Necas E. Protein kinase inhibitors. Folia Biol (Praha) 2006; 52: 137-148.
2. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-7109.
3. Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 2007; 59: 561-574.
4. Diamantis ML, Chon SY. Sorafenib-induced psoriasifrom eruption in a patient with metastatic thyroid carcinoma. J Drugs Dermatol 2010; 9: 169-171.
5. Smith KJ, Haley H, Hamza S, Skelton HG. Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors. Dermatol Surg 2009; 35: 1766-1770.
6. Kong HH, Turner ML. Array of cutaneous adverse effects associated with sorafenib. J Am Acad Dermatol 2009; 61: 360-361.
7. Raymond AK, Puri PK, Selim MA, Tyler DS, Nelson KC: Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb. Arch Dermatol 2010; 146: 1438-1439.
8. Autier J, Escudier B, Wechsler J, et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008; 144: 886-892.
9. Dubauskas Z, Kunishige J, Prieto VG, et al. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 2009; 7: 20-23.
10. Kong HH, Cowen EW, Azad NS, et al. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 2007; 56: 171-172.
11. Lacouture ME, Desai A, Soltani K, et al. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol 2006; 31: 783-785.
12. Arnault JP, Wechsler J, Escudier B, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009; 27: e59-e61.
13. Hong DS, Reddy SB, Prieto VG, et al. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol 2008; 144: 779-782.
14. Kwon EJ, Kish S, Jaworsky C. The histologic spectrum of epithelial neoplasms induced by sorafenib. J Am Acad Dermatol 2009; 61: 522-527.
15. Hasskarl J. Sorafenib: recent results. Cancer Res 2010; 184: 61-70.
16. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000; 42: 23-24.
17. Clausen OP, Aass HC, Beigi M, et al. Are keratoacanthomas variants of squamous cell carcinomas? A comparison of chromosomal aberrations by comparative genomic hybridization. J Invest Dermatol 2006; 126: 2308-2315.
18. Hodak E, Jones RE, Ackerman AB. Solitary keratocanthoma is a squamous-cell carcinoma: three examples with metastases. Am J Dermatopathol 1993; 16: 332-342.
19. Cribier B, Asch P, Grosshans E. Differentiating squamous cell carcinoma from keratocanthoma using histopathological criteria. Is it possible? A study of 296 cases. Dermatology 1999; 199: 208-212.
20. Magalhães RF, Cruvinel GT, Cintra GF, et al. Diagnosis and follow-up of keratoacanthoma-like lesions: clinical-histologic study of 43 cases. J Cutan Med Surg 2008; 12: 163-173.
21. Patel A, Haliday GM, Cooke BE, Barnetson RS. Evidence that regression of keratocanthoma is immunologically mediated: a comparison with squamous cell carcinoma. Br J Dermatol 1994; 131: 789-798.
22. Goldenhersh MA, Olsen TG. Invasive squamous cell carcinoma initially diagnosed as a giant keratoacanthoma. J Am Acad Dermatol 1984; 10: 372-378.
23. Ledo E. Wart, keratocanthoma and squamous cell carcinoma: a spectrum of the same neoplastic process? Int J Dermatol 1992; 31: 777-778.
24. Mandrell JC, Santa Cruz D. Keratoacanthoma: hyperplasia, benign neoplasm, or a type of squamous cell carcinoma? Semin Diagn Pathol 2009; 26: 150-163.
25. Blessing K, Nafussi AAL, Gordon PM. The regressing keratocanthoma. Histopathology 1994; 24: 381-384.
26. Schwartz RA: Keratoacanthoma: a clinico-pathologic enigma. Dermatol Surg 2004; 30: 326-333.
27. Schwartz RA: Keratoacanthoma. J Am Acad Dermatol 1994; 30: 1-19.
28. Jensen P, Clausen OPF, Bryne M. Difference in Sialyl-Tn antigen expression between keratocanthomas and cutaneous squamous cell carcinomas. J Cutan Pathol 1999; 26: 183-189.
29. Kerschmann RL, McCalmont TH, LeBoit PE. p53 onocoproteinexpression and prolifertation index in keratocanthoma and squamous cell carcinoma. Arch Dermatol 1994; 130: 181-186.
30. Putti TC, Teh M, Lee YS. Biological behavior of keratocanthomas and squamous cell carcinoma: telomerase activity and COX-2 as potential markers. Mod Pathol 2004; 17: 468-475.
31. Rass K, Reichrath J. UV damage and DNA repair in malignant melanoma and nonmelanoma skin cancer. Adv Exp Med Biol 2008; 624: 162-178.
32. Boukamp P. Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis 2005; 26: 1657-1667.
33. Corbalán-Vélez R, Ruiz-Maciá JA, Brufau C, Carapeto FJ. Cutaneous squamous cell carcinoma and human papillomavirus. Actas Dermosifiliogr 2007; 98: 583-593.
34. Harwood CA, Proby CM. Human papillomaviruses and non-melanoma skin cancer. Curr Opin Infect Dis 2002; 15: 101-114.
35. Masini C, Fuchs PG, Gabrielli F, et al. Evidence for the association of human papillomavirus infection and cutaneous squamous cell carcinoma in immunocompetent individuals. Arch Dermatol 2003; 139: 890-894.
36. Harwood CA, Surentheran T, Sasieni P, et al. Increased risk of skin cancer associated with the presence of epidermodysplasia verruciformis human papillomavirus types in normal skin. Br J Dermatol 2004; 150: 949-957.
37. Purdie KJ, Surentheran T, Sterling JC, et al. Human papillomavirus gene expression cutaneous squamous cell carcinomas from immunosuppressed and immunocompetent individuals. J Invest Dermatol 2005; 125: 98-107.
38. Hipp MM, Hilf N, Walter S, et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 2008; 111: 5610-5620.
39. Zitzmann K, von RüdenJ, Brand S, et al. Compensatory activation of Akt in response to mTOR and Raf inhibitors-A rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett 2010; 295: 100-109. Mar 29. [Epub ahead of print].
40. Zhang Y-L, Keng Y-F, Zhao Y, et al. Suramin is an active site-directed, reversible, and tight-binding inhibitor of protein-tyrosine phosphatase. J Biol Chem 1998; 273: 12282-12287.
41. Kobayashi K, Pezen DS, Vogaelzang NJ, et al. Keratocanthomas and skin neoplasms associated with suramin therapy. Arch Dermatol 1996; 132: 96-98.
42. Kenner JR, Sperling LC, Waseluko J, et al. Suramin keratosis: a unique skin eruption in a patient receiving suramin for metatstatic prostate cancer. J Urol 1997; 158: 2245-2246.